708274-24-2

Basic information

• Product Name: 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-[3-(trifluoromethyl)phenyl]-
• CAS NO: 708274-24-2
• Molecular Formula: C11H8F3NO3
• Molecular Weight: 259.185
• Mol File: 708274-24-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-[3-(trifluoromethyl)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-[3-(trifluoromethyl)phenyl]-(708274-24-2)
• EPA Substance Registry System: 5-Isoxazolecarboxylic acid, 4,5-dihydro-3-[3-(trifluoromethyl)phenyl]-(708274-24-2)

Safety Data

• Hazardous Substances Data: 708274-24-2(Hazardous Substances Data)

Upstream product

• 368-83-2 3-(trifluoromethyl)benzaldehyde oxime 
• 69053-93-6 α-chloro-(3-trifluoromethylbenzaldehyde)oxime 
• 454-89-7 3-Trifluoromethylbenzaldehyde 
• 708274-23-1 methyl 3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazole-5-carboxylate 

Downstream Products

• 1174749-33-7 N-[3-(4-{4-(3-(3-trifluoromethyl-phenyl)-4,5-dihydro-isoxazole-5-carbonyl)-piperazin-1-yl}-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide 
• 1394830-06-8 (3S)-1-(3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazol-5-ylcarbonyl)-pyrrolidin-3-amine hydrochloride 
• 857651-07-1 tert-butyl [(3S)-1-(3-[3-(trifluoromethyl)phenyl]-4,5-dihydroisoxazol-5-ylcarbonyl)pyrrolidin-3-yl]carbamate 

Relevant articles and documents

A METHOD OF TREATING LIVER FIBROSIS

The present invention relates to a method of treating hepatis C and/or liver fibroisis with 3-cycloalkylaminopyrrolidine derivatives of the present invention

3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors

The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as modulators of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.